Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coronavirus / COVID-19 Pandemic -- Ignore unavailable to you. Want to Upgrade?

To: Glenn Petersen who wrote (12607)	2/1/2021 10:31:46 AM
From: Thomas M.	1 Recommendation Recommended By Cogito Ergo Sum Read Replies (1) \| Respond to of 22882

He then made a point that he’d repeat throughout the coming months: The FDA would rigorously follow data in approving only safe and effective treatments. In other words, despite the frantic search for COVID-19 remedies, there would be no back door to FDA approval Except that's EXACTLY what he did. He gave back door approval to Remdesivir despite poor data. Message 32717256 And they overhyped another round of poor data in the summer: The agency last month expanded use to hospitalized patients who do not require oxygen support, based on data published in the JAMA medical journal showing that the drug provided a modest benefit for those patients. The newer data has left many experts unconvinced. "I am not terribly impressed with the study," said Dr. Adarsh Bhimraj, an infectious disease specialist at the Cleveland Clinic. He said he remains "skeptical" about using remdesivir in patients with moderate COVID-19, especially given the price. usnews.com Big global study finds remdesivir doesn't help Covid-19 patients cnn.com Tom